BIG Impact invests in autoimmune diagnostics and drug discovery startup AOI Biosciences
Reuters2026/09/15 00:19Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
- BIG Impact Inc completed an investment in AOI Biosciences, a Japan-based diagnostics and drug-discovery company focused on autoimmune diseases.
- AOI Biosciences commercializes proprietary antibody testing with domestic and overseas medical institutions.
- The company is building a drug-discovery platform using quantum-related technology, targeting autoimmune disease and infectious disease programs.
Disclaimer:
This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BIG Impact Inc published the original content used to generate this news brief on September 15, 2026, and is solely responsible for the information contained therein.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Data: US XRP spot ETF saw a net inflow of 11.255 million USD in a single day
Chaincatcher•2026/09/15 01:34
Delta Thailand returns to FTSE4Good ESG index for eighth time
Reuters•2026/09/15 01:27
Impact Biomedical to execute 1-for-12.62 reverse stock split Sept. 23
Reuters•2026/09/15 01:27
Titomic wins US$5 million U.S. Air Force contract for cold spray system at Tinker AFB
Reuters•2026/09/15 01:15
